Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quinapril hydrochloride, quantity: 10.832 mg (equivalent: quinapril, qty 10 mg) - tablet, film coated - excipient ingredients: magnesium carbonate hydrate; crospovidone; povidone; colloidal anhydrous silica; calcium sulfate dihydrate; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin - hypertension: quinapril hydrochloride tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril tablets in renovascular hypertension. congestive heart failure: quinapril hydrochloride tablets are indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - quinapril hydrochloride, quantity: 21.664 mg (equivalent: quinapril, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; magnesium carbonate hydrate; colloidal anhydrous silica; povidone; calcium sulfate dihydrate; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin - hypertension: quinapril hydrochloride tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril tablets in renovascular hypertension. congestive heart failure: quinapril hydrochloride tablets are indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - quinapril hydrochloride, quantity: 10.832 mg (equivalent: quinapril, qty 10 mg) - tablet, film coated - excipient ingredients: magnesium carbonate hydrate; crospovidone; colloidal anhydrous silica; povidone; magnesium stearate; calcium sulfate dihydrate; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin - hypertension: quinapril hydrochloride tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril tablets in renovascular hypertension. congestive heart failure: quinapril hydrochloride tablets are indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - quinapril hydrochloride, quantity: 5.416 mg (equivalent: quinapril, qty 5 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; povidone; crospovidone; calcium sulfate dihydrate; magnesium stearate; magnesium carbonate hydrate; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin - hypertension: quinapril hydrochloride tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril tablets in renovascular hypertension. congestive heart failure: quinapril hydrochloride tablets are indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

Vương quốc Anh - Tiếng Anh - MHRA (Medicines & Healthcare Products Regulatory Agency)

crescent pharma ltd - oxytetracycline dihydrate - oral tablet - 250mg

Vương quốc Anh - Tiếng Anh - MHRA (Medicines & Healthcare Products Regulatory Agency)

dalkeith laboratories ltd - oxytetracycline dihydrate - oral tablet - 250mg

Bỉ - Tiếng Anh - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

kela sa-nv - oxytetracycline hydrochloride 863,2 mg/g - eq. oxytetracycline 800 mg/g - powder for use in drinking water/milk - 863,20 mg/g - oxytetracycline hydrochloride 863.2 mg/g - oxytetracycline - cattle; pig

Kenya - Tiếng Anh - Pharmacy and Poisons Board

alfasan international kuipersweg 9 - 3449 ja woerden holland netherlands - oxytetracycline - injection - oxytetracycline 10% - antibacterials for systemic use: quinolone

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

par pharmaceutical, inc. - tetracycline hydrochloride (unii: p6r62377kv) (tetracycline - unii:f8vb5m810t) - tetracycline hydrochloride 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride tablets should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. tetracycline hydrochloride tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: - upper respiratory tract infections caused by streptococcus pyogenes , streptococcus pneumoniae and hemophilus influenzae . note: tetracycline hydrochloride tablets should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. - lower respiratory tra

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

breckenridge pharmaceutical, inc. - tetracycline hydrochloride (unii: p6r62377kv) (tetracycline - unii:f8vb5m810t) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: - upper respiratory tract infections caused by streptococcus pyogenes , streptococcus pneumoniae and hemophilus influenzae . note: tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. - lower respiratory tract infections caused by streptococcus pyogenes, strep